In March and April last year, despair gripped hundreds of Ecuadorian families who were looking for various medications to combat the SARS-CoV-2 virus, which triggered respiratory problems in their relatives. Among these drugs was Hydroxychloroquine, which had been depleted due to its high consumption or the hoarding of certain people in those days.
Many used social media to plead for the medicine to be sold to them. Those channels became showcases for supply and demand. Something that was replicated in other parts of the world. Amid the chaos, scientific criteria for and against the use of Hydroxychloroquine and Chloroquine were disseminated.
Today, the latest evidence found by studies conducted in China and France definitively dismisses hydroxychloroquine as a possible treatment for the new coronavirus. These evidences rule out hydroxychloroquine for patients with COVID, collects a publication from the specialized portal on health, Medical Writing.
“Some adverse events occurred in the (150) patients taking this drug in the study. This is a randomized clinical trial showing that ‘hospitalized patients with mild to moderate persistent COVID-19 receiving hydroxychloroquine do not clear the virus further rapidly than those receiving standard care. Adverse events were greater in those receiving hydroxychloroquine, “the publication reports, and it is detailed that half of individuals received Hydroxychloroquine in addition to standard care and the others received only standard care (control group). .
By day 28, it is detailed, testing revealed similar rates of COVID-19 in the two groups, but adverse events were more common in those who received the drug. Among the adverse events were heart problems.
Hydroxychloroquine is a medicine used to treat various autoimmune diseases, such as lupus and rheumatoid arthritis. The shortage of the drug in the wave of infections in Guayaquil generated more than one problem for those who suffer from these diseases.
Almost simultaneously, the findings of another study, conducted in France, with similar conclusions on the effects of Hydroxychloroquine in patients with COVID-19, were known. Currently there are more than 4 million positive cases worldwide.
The Infobae portal reports on its website that the chloroquine derivative “does not significantly reduce the risk of admission to resuscitation or death in hospitalized patients with pneumonia caused by COVID-19”.
Of 181 patients, 84 received hydroxychloroquine within 48 hours of hospitalization and 97 did not (control group), detailed in the Medical Writing article.
“They found no significant difference between the groups for transfer to intensive care, death within 7 days, or development of acute respiratory distress syndrome within 10 days.
The researchers say caution is needed in interpreting their results, but their findings “do not support the use of hydroxychloroquine in hospitalized patients with COVID-19 pneumonia,” reports the news release.
Alert in Spain
The Spanish Agency of Medicines and Health Products (Aemps) issued an alert about the effects that chloroquine and hydroxychloroquine can generate in the body, drugs used to treat people affected by the new coronavirus, according to the portal 20 minutes, due to what “They can lead to neuropsychiatric disorders, such as acute psychosis, attempted suicide, or completed suicide.”
This agency of the Ministry of Health published on its website that some serious cases of patients with COVID-19 treated with hydroxychloroquine have been reported. “In these cases, behavioral disorders appeared mainly during the first days with the medication,” it was noted.
The Aemps explained that “although the appearance of these psychiatric symptoms may be influenced by other factors that may be present in each patient, such as, for example, the disease itself, these reactions are described for chloroquine and hydroxychloroquine.” (I)